Spero Therapeuti Stock Price, News & Analysis

Spero Therapeutics announced positive topline results from its pivotal Phase 3 trial of oral tebipenem HBr, indicating statistical non-inferiority to intravenous ertapenem for treating complicated urinary tract infections (cUTI) and acute pyelonephritis. The trial included 1,372 patients and demonstrated overall response rates of 58.8% for tebipenem HBr compared to 61.6% for ertapenem. Tebipenem HBr had a comparable safety profile, with treatment-emergent adverse events reported in about 26% of patients. Spero plans to submit a NDA to the FDA in Q2 2021.

Spero Therapeutics (Nasdaq: SPRO) announced the FDA's acceptance of its Investigational New Drug application for SPR720, an oral antimicrobial targeting nontuberculous mycobacterial (NTM) pulmonary disease. This acceptance allows Spero to initiate a Phase 2a trial by the end of 2020, involving around 90 patients. SPR720 aims to fulfill a critical unmet need for NTM infections, as it is the first oral antibiotic being developed specifically for this condition. It also has QIDP and orphan drug designations from the FDA, enhancing its development prospects.

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on July 31, 2020, that its Compensation Committee granted non-qualified stock options to purchase 22,000 shares to two new employees, as part of the 2019 Inducement Equity Incentive Plan. The options have an exercise price of $11.70 per share, equal to the closing stock price on that date, vesting over four years. This plan is designed to attract talent by offering inducements for new hires who have not previously been employed by Spero.

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 30, 2020, the granting of non-qualified stock options for 40,000 shares to five new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $13.53 per share, will vest over four years, with 25% vesting after the first year. This incentive is in accordance with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent in the biopharmaceutical sector focused on treating multi-drug resistant bacterial infections and rare diseases.

Spero Therapeutics (Nasdaq: SPRO) will present a corporate update at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:00 a.m. ET. The presentation will be led by Ankit Mahadevia, M.D., President and CEO. Interested individuals can access the webcast on Spero's website under the 'Events and Presentations' section. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, including its lead product candidate, tebipenem HBr, aimed at treating MDR Gram-negative infections.

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 1, 2020, the grant of stock options totaling 29,500 shares to four new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $11.82 per share, vest over four years, incentivizing employee retention. This grant aligns with Nasdaq Listing Rule 5635(c)(4), allowing equity awards to non-employees as a recruitment tool. Spero focuses on treating multi-drug resistant infections and rare diseases, advancing key candidates like tebipenem HBr for MDR infections and SPR720 for a rare disease associated with NTM.

Spero Therapeutics (Nasdaq: SPRO) has completed enrollment in its pivotal Phase 3 ADAPT-PO trial for tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) in approximately 1,370 patients. Top-line results are expected in Q3 2020. The company also plans to initiate a Phase 2a trial for SPR720, targeting non-tuberculous mycobacterial disease. Financially, Spero reported a Q1 2020 net loss of $23.3 million, significantly higher than the $5.1 million loss in Q1 2019. Total revenue dropped to $1.7 million from $7.7 million in the prior year due to reduced funding and collaboration revenue.

Spero Therapeutics (Nasdaq: SPRO) announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, for tebipenem HBr, targeting complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). This milestone involves over 1,370 subjects and aims to compare an oral regimen of tebipenem HBr against standard intravenous treatment. The company expects to report topline results in Q3 2020, emphasizing the unmet need for effective oral therapies to reduce hospitalizations caused by drug-resistant infections.